MOLECULAR PARTNERS AG Research and Development Expense
MOLECULAR PARTNERS AG (MOLN) reported Research and Development Expense of CHF 40.19 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-12
- MOLECULAR PARTNERS AG research and development expense for the quarter ending 2025-06-30 was 10.71M CHF, a 18.19% decline year-over-year.
- MOLECULAR PARTNERS AG research and development expense for the quarter ending 2024-06-30 was 13.09M CHF, a 12.51% increase year-over-year.
- MOLECULAR PARTNERS AG research and development expense for the quarter ending 2023-06-30 was 11.63M CHF, a 7.47% decline year-over-year.
- MOLECULAR PARTNERS AG research and development expense for the quarter ending 2022-06-30 was 12.57M CHF.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|---|
| 2025-12-31 | 40.19M CHF 20-F · filed 2026-03-12 | ||
| 2025-06-30 | 10.71M CHF 6-K · filed 2025-08-25 | 22.63M CHF 6-K · filed 2025-08-25 | |
| 2024-12-31 | 48.60M CHF 20-F · filed 2026-03-12 | ||
| 2024-06-30 | 13.09M CHF 6-K · filed 2025-08-25 | 27.19M CHF 6-K · filed 2025-08-25 | |
| 2023-12-31 | 48.78M CHF 20-F · filed 2026-03-12 | ||
| 2023-06-30 | 11.63M CHF 6-K · filed 2024-08-26 | 24.33M CHF 6-K · filed 2024-08-26 | |
| 2022-12-31 | 50.75M CHF 20-F · filed 2025-03-06 | ||
| 2022-06-30 | 12.57M CHF 6-K · filed 2023-08-24 | 27.04M CHF 6-K · filed 2023-08-24 | |
| 2021-12-31 | 55.72M CHF 20-F · filed 2024-03-14 | ||
| 2021-06-30 | 31.58M CHF 6-K/A · filed 2022-08-31 | ||
| 2020-12-31 | 56.08M CHF 20-F · filed 2023-03-09 | ||
| 2019-12-31 | 43.50M CHF 20-F · filed 2022-03-15 |